Humanigen seeks FDA approval for COVID-19 drug

By The Science Advisory Board staff writers

Humanigen requested an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to use its drug lenzilumab in hospitalized COVID-19 patients.

This application follows positive results from the LIVE-AIR phase III clinical trial that showed lenzilumab improved the likelihood of survival without ventilation in newly hospitalized COVID-19 patients.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?